Matches in Nanopublications for { ?s <http://www.w3.org/2000/01/rdf-schema#label> ?o ?g. }
- association label "The majority of antipsychotic use in children in Alberta is off-label and associated with disruptive behavior disorders, depression, and anxiety disorders. (...) Information available in Table 1." assertion.
- context label "children and adolescents" assertion.
- association label "The majority of antipsychotic use in children in Alberta is off-label and associated with disruptive behavior disorders, depression, and anxiety disorders. (...) Information available in Table 1." assertion.
- context label "children and adolescents" assertion.
- association label "The majority of antipsychotic use in children in Alberta is off-label and associated with disruptive behavior disorders, depression, and anxiety disorders. Quetiapine was mainly prescribed for neurotic disorder or depression, while aripiprazole was prescribed most frequently for conduct disorder or neurotic disorders. (...) Information available in Table 1." assertion.
- context label "children and adolescents" assertion.
- association label "The majority of antipsychotic use in children in Alberta is off-label and associated with disruptive behavior disorders, depression, and anxiety disorders. (...) Information available in Table 1." assertion.
- context label "children and adolescents" assertion.
- association label "The majority of antipsychotic use in children in Alberta is off-label and associated with disruptive behavior disorders, depression, and anxiety disorders. (...) Information available in Table 1." assertion.
- context label "children and adolescents" assertion.
- association label "The majority of antipsychotic use in children in Alberta is off-label and associated with disruptive behavior disorders, depression, and anxiety disorders. (...) Information available in Table 1." assertion.
- context label "adults" assertion.
- association label "It is licensed to treat depression, but it is also commonly used off-label to treat insomnia." assertion.
- context label "Children 3 to 5 years" assertion.
- association label "The most commonly prescribed off-label prescriptions for children ages 3 to 5 years were methylphenidate and alpha agonist formulations" assertion.
- context label "Children 3 to 5 years" assertion.
- association label "Clonidine and guanfacine (immediate and extended release combined) accounted for 42.6% (952/2233) of the off-label prescriptions written for the 3- to 5-year-old age group." assertion.
- context label "Children 3 to 5 years" assertion.
- association label "Clonidine and guanfacine (immediate and extended release combined) accounted for 42.6% (952/2233) of the off-label prescriptions written for the 3- to 5-year-old age group." assertion.
- context label "Children 3 to 5 years" assertion.
- association label "The 2 other medications for which off-label prescriptions were written for children ages 3 to 5-years included dexmethylphenidate, both immediate (20/2233) and extended release (20/2233), and lisdexamfetamine (42/2233)." assertion.
- DB06701 label "Dexmethylphenidate" assertion.
- context label "Children 3 to 5 years" assertion.
- association label "In our study, extended-release dextroamphetamine-containing medications represented 8% (180/2233) of the overall off-label prescribing in children 3 to 5 years old and, as with methylphenidate, larger doses (25–30 mg) of dextroamphetamine were noted." assertion.
- context label "Children 3 to 5 years" assertion.
- association label "Dextroamphetamine-containing extended-release formulations (n = 180) and atomoxetine (n = 103) were also frequently prescribed off-label medications for children ages 3 to 5 years (8.1% and 4.6%, respectively)." assertion.
- context label "Children 3 to 5 years" assertion.
- association label "The 2 other medications for which off-label prescriptions were written for children ages 3 to 5-years included dexmethylphenidate, both immediate (20/2233) and extended release (20/2233), and lisdexamfetamine (42/2233)." assertion.
- context label "Adults" assertion.
- association label "Valproate and carbamazepine are commonly used empirically (off-label) for putative long-term mood-stabilizing effects" assertion.
- wf-wp13-cultural-heritage label "WorldFAIR WP13 CULTURAL HERITAGE" assertion.
- europeana-data-model label "TEST Europeana Data Model" assertion.
- indigeo label "indigeo - Environmental data and geospatial information infrastructure UMR LETG • OSU IUEM • ZABrI" assertion.
- geonetwork-api label "GeoNetwork API" assertion.
- cc-by-4-0 label "Creative Commons Attribution 4.0 International (CC BY 4.0) " assertion.
- ThermoML label "IUPAC XML-based Standard for Thermodynamic Property Data" assertion.
- GoldBook label "IUPAC Gold Book " assertion.
- AIF label "IUPAC Adsorption Information File" assertion.
- FAIRSpec label "IUPAC Standard for FAIR Data Management of Spectroscopic Data" assertion.
- RInChI label "IUPAC Standard InChI-based Representation of Chemical Reactions" assertion.
- CrossRef label "CrossRef Metadata Consortium " assertion.
- europeana-dm label "Europeana Data Model for Cultural Heritage (EDM)" assertion.
- europeana-dm label "Europeana Data Model for Cultural Heritage (EDM)" assertion.
- europeana label "Europeana" assertion.
- edugate-HEAnet label "Edugate" assertion.
- IIIF label "International Image Interoperability Framework (IIIF)" assertion.
- IIIF label "International Image Interoperability Framework (IIIF)" assertion.
- Crossref label "Crossref (DOI)" assertion.
- DDI-C label "DDI-Codebook" assertion.
- ICPSR label "Inter University Consortium for Political and Social Research" assertion.
- SALURBAL-portal label "SALURBAL-data-portal" assertion.
- MONDO_0006731 label "hyperactivity" assertion.
- 1993 label "methacholine" assertion.
- MONDO_0005132 label "CMV infection" assertion.
- UBERON_2005051 label "CMV" assertion.
- MONDO_0006652 label "STEMI" assertion.
- MONDO_0006652 label "STEMI" assertion.
- MONDO_0003019 label "hypokalemia" assertion.
- 16230 label "Amiloride hydrochloride" assertion.
- 3639 label "hydrochlorothiazide" assertion.
- 3639 label "hydrochlorothiazide" assertion.
- 5462222 label "potassium" assertion.
- D049971 label "thiazides" assertion.
- MONDO_0009960 label "Crohn's disease" assertion.
- MONDO_0009960 label "Crohn's disease" assertion.
- MONDO_0009960 label "ulcerative colitis" assertion.
- FYS6T7F842 label "Adalimumab" assertion.
- CHEBI_8735 label "™" assertion.
- MONDO_0005045 label "HCM" assertion.
- OMIM_MTHU037025 label "obstructive hypertrophic cardiomyopathy" assertion.
- 117761397 label "CAMZYOS" assertion.
- C0263630 label "hypertrophic" assertion.
- MONDO_0005021 label "dilated cardiomyopathy" assertion.
- 132999 label "Ivabradine" assertion.
- MONDO_0005920 label "P. falciparum" assertion.
- MONDO_0005921 label "P. vivax" assertion.
- MONDO_0018661 label "Zika" assertion.
- MONDO_0026767 label "COVID-19" assertion.
- MONDO_0026767 label "COVID-19" assertion.
- MONDO_0026767 label "COVID-19" assertion.
- MONDO_0100128 label "infections" assertion.
- MONDO_0100128 label "infections" assertion.
- NCBITaxon_5858 label "P. malariae" assertion.
- 886U3H6UFF label "Chloroquine" assertion.
- MONDO_0001875 label "epicondylitis" assertion.
- MONDO_0002471 label "bursitis" assertion.
- MONDO_0002471 label "bursitis" assertion.
- MONDO_0002471 label "bursitis" assertion.
- MONDO_0004855 label "tenosynovitis" assertion.
- MONDO_0004980 label "allergic" assertion.
- MONDO_0004980 label "allergic" assertion.
- MONDO_0004980 label "allergic" assertion.
- MONDO_0004980 label "allergic" assertion.
- MONDO_0005393 label "gouty arthritis" assertion.
- 6741 label "methylprednisolone" assertion.
- D003094 label "collagen" assertion.
- D003094 label "collagen" assertion.
- MONDO_0004907 label "alopecia areata" assertion.
- MONDO_0005348 label "keloids" assertion.
- MONDO_0006554 label "granuloma annulare" assertion.